Prostate cancer and the hypofractionation hypothesis

Journal of Clinical Oncology

Volumn 31, Issue 31, 2013, Pages 3849-3851

  Lee, W Robert ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL SURVIVAL; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; CONSENSUS; DOSE RESPONSE; EDITORIAL; HUMAN; HYPOFRACTIONATION; HYPOTHESIS; INTENSITY MODULATED RADIATION THERAPY; LINEAR ACCELERATOR; MAMMAL CELL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SAMPLE SIZE; SURVIVAL RATE; TELETHERAPY; MALE; PROCEDURES; PROSTATIC NEOPLASMS; METHODOLOGY; NOTE; PROSTATE TUMOR;

HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84891622685     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.4942     Document Type: Editorial

References (14)

1. Brenner DJ, Hall EJ: Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43:1095-1101, 1999 (Pubitemid 29144800)
2. Thames HD, Hendry JH: Fractionation in Radiotherapy. London, United Kingdom, Taylor & Francis, 1987
3. Friberg S, Ruden B: Rise and fall of hypofractionation in clinical radiotherapy in the 20th century. J Oncol 4:139e-148e, 2007
4. Brenner DJ, Hlatky LR, Hahnfeldt PJ, et al: The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships. Radiat Res 150:83-91, 1998 (Pubitemid 28285628)
5. Thames HD, Bentzen SM, Turesson I, et al: Time-dose factors in radiotherapy: A review of the human data. Radiother Oncol 19:219-235, 1990 (Pubitemid 20369216)
6. Vogelius IR, Bentzen SM: Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: Bad news, good news, or no news? Int J Radiat Oncol Biol Phys 85:89-94, 2013
7. Kaidar-Person O, Roach M 3rd, Crehange G: Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: A step forward. Int J Radiat Oncol Biol Phys 86:600-605, 2013
8. Pollack A, Walker G, Horwitz EM: Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31:3860-3868, 2013
9. Cabrera AR, Lee WR: Hypofractionation for clinically localized prostate cancer. Semin Radiat Oncol 23:191-197, 2013
10. Piaggio G, Elbourne DR, Pocock SJ, et al: Reporting of noninferiority and equivalence randomized trials: Extension of the CONSORT 2010 statement. JAMA 308:2594-2604, 2012
11. Kupelian PA, Willoughby TR, Reddy CA, et al: Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68:1424-1430, 2007 (Pubitemid 47176809)
12. Patel N, Faria S, Cury F, et al: Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: Long-term outcomes. Int J Radiat Oncol Biol Phys 86:534-539, 2013
13. Arcangeli S, Strigari L, Gomellini S, et al: Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84:1172-1178, 2012
14. Kuban DA, Nogueras-Gonzalez GM, Hamblin L, et al: Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys 78:S58-S59, 2010 (supp 3)